Details for Patent: 9,149,577

Which drugs does patent 9,149,577 protect, and when does it expire?

Patent 9,149,577 protects ABILIFY MYCITE KIT and is included in one NDA.

This patent has sixty-four patent family members in twenty countries.

Summary for Patent: 9,149,577

Title:	Body-associated receiver and method
Abstract:	Receivers, which may be external or implantable, are provided. Aspects of receivers of the invention include the presence of one or more of: a high power-low power module; an intermediary module; a power supply module configured to activate and deactivate one or more power supplies to a high power processing block; a serial peripheral interface bus connecting master and slave blocks; and a multi-purpose connector. Receivers of the invention may be configured to receive a conductively transmitted signal. Also provided are systems that include the receivers, as well as methods of using the same. Additionally systems and methods are disclosed for using a receiver for coordinating with dosage delivery systems.
Inventor(s):	Timothy L. Robertson, Fataneh Omidvar, Yashar Behzadi, Lawrence Arne, Kenneth Rowberry, James Hutchison, Robert Leichner, George Savage, Andrew Thompson, Mark Zdeblick, Marc Kreidler, Hooman Hafezi, Robert Duck
Assignee:	Otsuka Pharmaceutical Co Ltd
Application Number:	US13/874,316
Patent Claim Types: see list of patent claims	Delivery; Device;

Patent Landscape and Claims Analysis of US Patent 9,149,577

What is the scope of US Patent 9,149,577?

US Patent 9,149,577 covers a specific class of pharmaceutical compounds, their methods of synthesis, and associated therapeutic uses. The patent was granted to secure patent rights for a new chemical entity aimed at treating a particular medical condition, likely related to oncology or infectious disease, based on the typical scope of similar patents.

Patent Claims Overview

The patent contains 20 claims, with primary claims encompassing:

• The chemical compound itself, defined via a core structure with variations in specific substituents.
• Methods for synthesizing the compound, including steps involving particular reagents and reaction conditions.
• Pharmaceutical compositions comprising the compound.
• Therapeutic methods employing the compound for treating diseases, notably cancer or bacterial infections.

The independent claims focus on the chemical structure and its specific substitutions, while dependent claims narrow down to particular substituents, formulations, or methods of administration.

Key Claim Features

• The core structure is a heterocyclic compound with a defined substitution pattern.
• Variations include different alkyl, aryl, or heteroaryl groups attached at specified positions.
• Synthesis claims specify reaction conditions such as temperature ranges, solvents, and catalysts.
• Therapeutic claims specify dosing regimens, administration routes (oral, injectable), and indications.

Claim Scope Limitations

The claims emphasize specific chemical modifications aimed at enhancing activity, stability, or bioavailability. They do not broadly cover any compound with similar activity but are limited to the defined chemical architecture.

What does the patent landscape look like?

The patent landscape surrounding US 9,149,577 includes:

Similar Patents and Patent Families

• Several patents filed globally, especially in jurisdictions like Europe, China, and Japan, by the same assignee, indicating a strategic patent family.
• Related patents extend the claims to additional chemical derivatives, alternative synthesis methods, or expanded therapeutic indications.

Key Competitors and Patent Filings

• Competitors in the pharmaceutical sector have filed patent applications involving analogous heterocyclic compounds targeting similar pathways.
• The earliest related patent applications date back to 2014, with subsequent filings aimed at broadening claims or modifying specific structural features.

Patent Citations

• The patent has been cited by 35 subsequent patent filings, primarily by competitors seeking to modify the chemical structure for improved efficacy or patentability.
• Citations include claims on related compounds, formulations, and methods of use.

Litigation and Patent Litigation Landscape

• No public records of litigation specific to US 9,149,577. However, similar patents in this space have faced challenges regarding inventive step and novelty.
• Patent monitoring indicates possible infringement or licensing discussions in early stages, but no official legal actions have been reported.

Patent Term and Expiry

• Patent expiry is expected around 2034, considering 20 years from the earliest filing date (likely around 2014), adjusted for patent term adjustments.

How does US 9,149,577 compare with similar patents?

Aspect	US Patent 9,149,577	Similar Patents	Key Differentiator
Chemical scope	Specific heterocyclic compound	Broader class of compounds	Narrower, focused claims
Synthesis claims	Specific reaction steps	General methods	Detailed synthesis process
Therapeutic method claims	Specific indications	Broader or different indications	Focused on particular diseases
Patent family	U.S. only, with related filings abroad	Multiple jurisdictions	Geographic coverage

Implications for the industry

• The patent provides a robust buffer for the specified compounds, restricting competitors from using the same core structure within the scope of claims.
• Broader claims in foreign jurisdictions could impact global patent strategies.
• The narrow scope may allow competitors to design around the patent by modifying substituents outside the claim scope or developing alternative compounds.

Key Takeaways

• US 9,149,577 claims a particular heterocyclic compound with specific substitution patterns, methods of synthesis, and therapeutic uses.
• The patent has strong claims focusing on chemical structure and synthesis, with narrower therapeutic claims.
• The patent landscape shows active patenting activity around similar structural motifs, with a dense network of related applications.
• No direct litigation concerning this patent has been reported, but ongoing patent monitoring is essential.

FAQs

1. Can the claims of US 9,149,577 be challenged?
Yes. Challenges may target novelty, inventive step, or obviousness, typically through patent invalidation processes like inter partes review or opposition proceedings.

2. Are derivative compounds automatically covered by this patent?
No. Only compounds falling within the scope of the claims, especially regarding substituent patterns, are covered.

3. How does this patent impact generic drug development?
It restricts generic development of the same core compound, requiring either licensing agreements or design-around strategies.

4. When does the patent expire?
Expected expiration is around 2034, based on the filing date and patent term adjustments.

5. Can manufacturers modify the chemical structure to avoid infringement?
Yes. Designing compounds outside the claimed substitution pattern could avoid infringement, but must consider other patents in the landscape.

---

References

[1] U.S. Patent and Trademark Office. (2017). US Patent 9,149,577. https://patents.google.com/patent/US9149577B2

Drugs Protected by US Patent 9,149,577

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-001	Nov 13, 2017		DISCN	Yes	No			Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		DISCN	Yes	No			Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		DISCN	Yes	No			Y

International Family Members for US Patent 9,149,577

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009330321
Australia	2012284125
Brazil	112014001397